General Information


Our goal is to slow the progression of chronic kidney disease, or CKD, through the treatment of metabolic acidosis. We are a late-stage pharmaceutical company focused on the development and commercialization of our drug candidate, TRC101, a non-absorbed polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. We recently completed our pivotal Phase 3 clinical trial, TRCA-301, that met both its primary and secondary endpoints in a highly statistically significant manner (p<0.0001 for all primary and secondary endpoints).


Employees: 61
Founded: 2013
Contact Information
Address 7000 Shoreline Court Suite 201, South San Francisco, CA 94080, US
Phone Number (415) 429-7800
Web Address
View Prospectus: Tricida
Financial Information
Market Cap $659.4mil
Revenues $0 mil (last 12 months)
Net Income $-59.7 mil (last 12 months)
IPO Profile
Symbol TCDA
Exchange NASDAQ
Shares (millions): 11.7
Price range $19.00 - $19.00
Est. $ Volume $222.3 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ Cowen
CO-Managers -
Expected To Trade: 6/28/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change